Search / 153 results found

from
to
State
  • Updated

AMBLER, Pa., May 13, 2021 /PRNewswire/ -- Simplex Health, the leading provider of evidence-based medical nutrition therapies, and Axia Women's Health, one of the nation's largest independent women's health groups announce an expanded partnership to support gestational diabetes patients across Pennsylvania, New Jersey, Indiana, Ohio, and Kentucky. Simplex Health will work as a trusted partner to 400 providers within Axia – helping patients manage and improve their condition through Simplex's proprietary Low-Insulin Nutrition Interventions. The announcement comes on the heels of a successful two-year relationship with practices throughout Montgomery County, PA.

State
  • Updated

ABBOTTSTOWN, Pa., May 3, 2021 /PRNewswire-PRWeb/ -- Innovo Detox has earned The Joint Commission's Gold Seal of Approval® for Comprehensive Accreditation Manual for Behavioral Health Care and Human Services Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal is a symbol of quality that reflects a health care organization's commitment to providing safe and quality patient care.

If you enjoy spending time outdoors during the warmer months, it’s inevitable that you will run into pesky plants or annoying insects, especia…

State
  • Updated

KING OF PRUSSIA, Pa., April 29, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The approval, based on data from the PATH (Polyneuropathy And Treatment with Hizentra) Extension study, simplifies dosage adjustments between two safe and effective doses proven to prevent CIDP relapse - without the need for intravenous immune globulin treatment in the event of a relapse on the low dose. The PATH Extension study was a multicenter, open-label extension study to the Phase III PATH study that evaluated the long-term safety and efficacy of Hizentra 0.2 g/kg and 0.4 g/kg weekly doses in the maintenance treatment of CIDP.